Visitors Now:
Total Visits:
Total Stories:
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Gilead ends trial of ulcerative colitis treatment notes Abzena

Thursday, September 22, 2016 4:17
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Abzena plc (LON:ABZA) has noted US pharma Gilead Sciences Inc (Nasdaq:GILD)  decision to end the Phase II/III clinical study of GS-5745 in patients with ulcerative colitis. 

Abzena added the termination affects only only one indication out of five and Gilead has confirmed that its Phase II and III studies of GS-5745 in patients with gastric cancer, Crohn’s disease, rheumatoid arthritis and cystic fibrosis will continue as planned. 

The GS-5745 antibody includes Abzena’s Composite Human Antibody technology and is one of 12 of its products currently in clinical development through over 40 licence and option agreements.

Gilead said interim analysis of the unblinded efficacy and safety data contained insufficient evidence of a treatment benefit in the group of study patients randomized to receive either one of two doses of GS-5745.

Story by ProactiveInvestors

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.